The role of mirna for the treatment of mgmt unmethylated glioblastoma multiforme
Kirstein A, Schmid TE, Combs SE (2020)
Publication Type: Journal article, Review article
Publication year: 2020
Journal
Book Volume: 12
Article Number: 1099
Journal Issue: 5
Abstract
Glioblastoma multiforme (GBM) is the most common high-grade intracranial tumor in adults. It is characterized by uncontrolled proliferation, diffuse infiltration due to high invasive and migratory capacities, as well as intense resistance to chemo-and radiotherapy. With a five-year survival of less than 3% and an average survival rate of 12 months after diagnosis, GBM has become a focus of current research to urgently develop new therapeutic approaches in order to prolong survival of GBM patients. The methylation status of the promoter region of the O6-methylguanine–DNA methyltransferase (MGMT) is nowadays routinely analyzed since a methylated promoter region is beneficial for an effective response to temozolomide-based chemotherapy. Furthermore, several miRNAs were identified regulating MGMT expression, apart from promoter methylation, by degrading MGMT mRNA before protein translation. These miRNAs could be a promising innovative treatment approach to enhance Temozolomide (TMZ) sensitivity in MGMT unmethylated patients and to increase progression-free survival as well as long-term survival. In this review, the relevant miRNAs are systematically reviewed.
Involved external institutions
Germany (DE)How to cite
APA:
Kirstein, A., Schmid, T.E., & Combs, S.E. (2020). The role of mirna for the treatment of mgmt unmethylated glioblastoma multiforme. Cancers, 12(5). https://dx.doi.org/10.3390/cancers12051099
MLA:
Kirstein, Anna, Thomas E. Schmid, and Stephanie E. Combs. "The role of mirna for the treatment of mgmt unmethylated glioblastoma multiforme." Cancers 12.5 (2020).
BibTeX: Download